false 0001094038 --12-31 0001094038 2022-05-24 2022-05-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

May 24, 2022

Date of Report (Date of earliest event reported)

 

 

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37939   45-4497941

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3200 Southwest Freeway

Suite 2500

Houston, Texas

  77027
(Address of principal executive offices)   (Zip Code)

(713) 400-6400

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   MRKR   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐        

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.03

Amendments to Articles of Incorporation or Bylaws.

Amendment of Certificate of Incorporation

On May 25, 2022, Marker Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Certificate of Incorporation (the “Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors and stockholders previously approved the Certificate, which increases the authorized shares of common stock of the Company from 150,000,000 shares to 300,000,000 shares. The Certificate is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

On May 24, 2022, the Company held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). The stockholders considered seven proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 15, 2022. Of the 83,078,675 shares outstanding as of the record date, 57,295,876 shares, or 68.97%, were present virtually or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1: Election of seven nominees to serve as directors until the 2023 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

 

Name

   Votes For      Votes
Withheld
 

David Eansor

     30,753,440        2,083,729  

Steven Elms

     30,965,719        1,871,450  

Peter Hoang

     30,759,510        2,077,659  

David Laskow-Pooley

     31,082,497        1,754,672  

John Wilson

     29,558,131        3,279,038  

Juan Vera

     31,165,066        1,672,103  

Katharine Knobil

     31,146,424        1,690,745  

Broker Non-Votes: 24,458,707.

All nominees were elected.

Proposal No. 2: Approval, on an advisory basis, of the compensation of the Company’s named executive officers. The votes were cast as follows:

 

     Votes For      Votes
Against
     Abstained  

Advisory approval of named executive officer compensation

     28,164,404        4,400,809        271,957  

Broker Non-Votes: 24,458,706.

Proposal No. 3: Amendment of the Company’s Certificate of Incorporation to increase the authorized number of shares of Common Stock. The votes were cast as follows:

 

     Votes For      Votes
Against
     Abstained  

Amendment of Certificate of Incorporation

     48,008,847        8,680,304        606,723  

Broker Non-Votes: 0.


Proposal No. 4: Approval to adopt a series of alternate amendments to the Company’s Certificate of Incorporation to effect a reverse stock split where the board of directors will have the discretion to select the reverse stock split ratio from within a range between and including one-for three (1:3) and one-for-twelve (1:12). The votes were cast as follows:

 

     Votes For      Votes
Against
     Abstained  

Amendment approval for reverse stock split

     48,899,833        7,846,346        549,695  

Broker Non-Votes: 0.

Proposal No. 5: Approval to adopt a series of alternate amendments to the Company’s Certificate of Incorporation to effect an authorized shares reduction, with the specific number of authorized shares determined by a formula that is based on the ratio utilized for a reverse stock split. The votes were cast as follows:

 

     Votes For      Votes
Against
     Abstained  

Amendment to effectuate an authorized shares reduction

     49,446,472        6,871,753        977,646  

Broker Non-Votes: 0.

Proposal No. 6: Amendment of the Marker Therapeutics, Inc. 2020 Equity Incentive Plan (the “2020 Plan”), to, among other things, increase the number of shares of common stock authorized for issuance under the 2020 Plan by 8,500,000 shares. The votes were cast as follows:

 

     Votes For      Votes
Against
     Abstained  

Amendment to the 2020 Equity Inventive Plan

     27,591,624        4,896,423        349,123  

Broker Non-Votes: 24,458,706.

Proposal No. 7: Ratification of the selection of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022. The votes were cast as follows:

 

     Votes For      Votes
Against
     Abstained  

Ratification of appointment of Marcum LLP

     52,918,715        3,807,322        569,839  

Broker Non-Votes: 0.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

    No.    

  

Description

 3.1    Certificate of Amendment to Certificate of Incorporation of Marker Therapeutics, Inc.
104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Marker Therapeutics, Inc.
Dated: May 27, 2022     By:  

    /s/ Anthony Kim

          Anthony Kim
          Chief Financial Officer
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Marker Therapeutics Charts.
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Marker Therapeutics Charts.